IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.929
AS - Asia 7.617
SA - Sud America 1.694
EU - Europa 1.204
Continente sconosciuto - Info sul continente non disponibili 410
AF - Africa 160
OC - Oceania 16
AN - Antartide 1
Totale 20.031
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.582
SG - Singapore 4.909
BR - Brasile 1.375
CN - Cina 1.044
VN - Vietnam 785
IT - Italia 501
HK - Hong Kong 269
CA - Canada 148
GB - Regno Unito 146
AR - Argentina 121
BD - Bangladesh 98
MX - Messico 97
DE - Germania 96
IN - India 93
FR - Francia 90
ZA - Sudafrica 64
IQ - Iraq 57
EC - Ecuador 54
ID - Indonesia 45
PL - Polonia 43
ES - Italia 40
JP - Giappone 40
RU - Federazione Russa 40
NL - Olanda 36
CO - Colombia 33
TR - Turchia 33
VE - Venezuela 30
UA - Ucraina 28
PK - Pakistan 27
FI - Finlandia 25
MY - Malesia 25
SE - Svezia 22
PY - Paraguay 21
JM - Giamaica 20
MA - Marocco 20
PH - Filippine 20
UY - Uruguay 20
CL - Cile 19
AE - Emirati Arabi Uniti 18
UZ - Uzbekistan 18
EG - Egitto 17
SA - Arabia Saudita 17
CR - Costa Rica 16
CZ - Repubblica Ceca 16
DZ - Algeria 16
NP - Nepal 16
KE - Kenya 15
LT - Lituania 15
IE - Irlanda 13
TT - Trinidad e Tobago 13
AU - Australia 12
JO - Giordania 12
TN - Tunisia 12
KZ - Kazakistan 11
AT - Austria 10
BO - Bolivia 10
AL - Albania 9
GT - Guatemala 9
PE - Perù 9
PS - Palestinian Territory 9
CH - Svizzera 8
KR - Corea 8
SV - El Salvador 8
IL - Israele 7
OM - Oman 7
PT - Portogallo 7
DO - Repubblica Dominicana 6
EE - Estonia 6
HN - Honduras 6
NI - Nicaragua 6
NO - Norvegia 6
AZ - Azerbaigian 5
BE - Belgio 5
DK - Danimarca 5
GR - Grecia 5
LB - Libano 5
RO - Romania 5
TH - Thailandia 5
BA - Bosnia-Erzegovina 4
CW - ???statistics.table.value.countryCode.CW??? 4
IR - Iran 4
KG - Kirghizistan 4
KW - Kuwait 4
NG - Nigeria 4
PR - Porto Rico 4
BB - Barbados 3
BH - Bahrain 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CY - Cipro 3
ET - Etiopia 3
GP - Guadalupe 3
HR - Croazia 3
LK - Sri Lanka 3
MD - Moldavia 3
RS - Serbia 3
SI - Slovenia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AG - Antigua e Barbuda 2
Totale 19.591
Salva come PNG Salva come JPEG
Città #
Singapore 1.920
San Jose 1.384
Ashburn 1.092
The Dalles 848
Dallas 495
Council Bluffs 439
Shanghai 342
Beijing 330
Santa Clara 300
Ho Chi Minh City 287
Hong Kong 252
Hanoi 171
Milan 137
Los Angeles 133
São Paulo 122
Boardman 110
New York 106
North Bergen 88
Phoenix 87
Rome 71
Atlanta 61
Chicago 54
Seattle 51
Rio de Janeiro 48
Brooklyn 46
Mexico City 46
Da Nang 37
Belo Horizonte 36
Warsaw 36
Buffalo 35
Johannesburg 34
Montreal 34
Orem 34
Tokyo 34
San Francisco 32
Chandler 30
Toronto 30
Charlotte 29
London 29
Brasília 28
Haiphong 28
Houston 26
Queens 26
Boston 25
Dhaka 25
Philadelphia 25
Curitiba 24
Helsinki 23
Turin 22
Guayaquil 21
Naples 21
Hải Dương 20
Miami 20
Denver 19
Campinas 18
Detroit 18
Paris 18
Ribeirão Preto 18
Wilmington 18
Baghdad 17
Jacksonville 17
Manchester 17
Amsterdam 16
Columbus 16
Kingston 16
Montevideo 16
Porto Alegre 16
Princeton 16
Stockholm 16
Frankfurt am Main 15
Quito 15
Tashkent 15
Ankara 14
Assago 14
Bologna 14
Cape Town 14
Goiânia 14
Las Vegas 14
Louisville 14
Newark 14
San José 14
Hillsboro 13
San Diego 13
Asunción 12
Bari 12
Chennai 12
Kuala Lumpur 12
Long Beach 12
Milwaukee 12
Munich 12
Reston 12
Sorocaba 12
Amman 11
Biên Hòa 11
Bogotá 11
Buenos Aires 11
Caxias do Sul 11
Cleveland 11
Dublin 11
Memphis 11
Totale 10.449
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 225
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer 190
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma 174
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 152
Morbidity And Complication Of Minimally Invasive Staging For Apparent Early-Stage Epithelial Ovarian Cancer: A Preliminary Analysis Of REMISSION Study 135
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 115
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix 111
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 108
Pembrolizumab for locally advanced cervical cancer - Authors' reply 100
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 98
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 97
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 92
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer 92
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey 92
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 88
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 88
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 87
Uterine serous carcinoma 83
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 82
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial 81
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 80
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 80
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 79
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 79
Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis 78
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment 77
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study 77
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 77
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) 76
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 75
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? 75
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 74
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study 73
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 73
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy 73
"Tumori della vulva e della vagina" 73
Advances in laparoscopic surgery for cervical cancer 72
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 72
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 72
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 72
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis 71
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 71
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial 70
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 70
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 70
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 70
Survival with Cemiplimab in Recurrent Cervical Cancer 69
A critical assessment on the role of sentinel node mapping in endometrial cancer 69
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 68
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach 66
Peritoneal cytology as prognostic factor in cervical cancer 66
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 66
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 66
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors 66
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 66
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 66
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 65
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 65
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 65
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 64
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 64
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib 64
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 64
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 64
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer 64
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study 63
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 63
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 62
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 62
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance 61
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy 61
Clear cell carcinoma of the endometrium 60
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 60
Trabectedin as a chemotherapy option for patients with BRCA deficiency 60
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA 59
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial 59
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 59
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile 59
Nomogram-based prediction of cervical dysplasia persistence/recurrence 59
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 59
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 58
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial 58
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 58
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial 58
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors 58
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 58
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 57
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary 57
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 57
Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease 57
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 57
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 57
Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. 57
How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy? 57
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 56
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy 56
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial 56
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer 56
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer 55
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary 55
Totale 7.510
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.371
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202217 0 0 0 2 0 0 0 2 1 2 4 6
2022/202387 13 2 7 13 2 8 0 11 16 9 5 1
2023/2024907 6 5 11 3 0 8 2 0 271 21 187 393
2024/20254.263 82 108 147 44 17 297 336 248 683 1.105 623 573
2025/202610.760 1.630 778 648 981 378 614 2.932 520 566 727 413 573
2026/20273.969 580 844 1.754 791 0 0 0 0 0 0 0 0
Totale 20.031